What is HC Wainwright’s Forecast for LifeMD Q3 Earnings?

LifeMD, Inc. (NASDAQ:LFMD) – Equities research analysts at HC Wainwright issued their Q3 2027 earnings per share estimates for shares of LifeMD in a report released on Tuesday, May 26th. HC Wainwright analyst Y. Chen forecasts that the company will earn $0.06 per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is $0.04 per share.

LFMD has been the topic of a number of other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of LifeMD in a research report on Monday, May 4th. Mizuho upgraded LifeMD from a “neutral” rating to an “outperform” rating and increased their target price for the company from $6.00 to $8.00 in a research report on Monday, March 16th. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Loop Capital set a $10.00 target price on LifeMD in a research report on Thursday, March 12th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Price Performance

Shares of NASDAQ:LFMD opened at $4.57 on Thursday. LifeMD has a 1 year low of $2.56 and a 1 year high of $15.84. The firm has a market capitalization of $221.01 million, a price-to-earnings ratio of 91.42 and a beta of 2.03. The business’s 50 day moving average price is $4.16 and its 200-day moving average price is $3.78.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The business had revenue of $50.16 million for the quarter, compared to analysts’ expectations of $48.84 million.

Institutional Investors Weigh In On LifeMD

A number of hedge funds have recently modified their holdings of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after acquiring an additional 2,235 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. SG Americas Securities LLC boosted its position in LifeMD by 13.8% during the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after acquiring an additional 3,061 shares during the last quarter. Invesco Ltd. boosted its position in LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after acquiring an additional 3,870 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after acquiring an additional 4,281 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.